# ALESIA (NCT02838420)

> A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: alectinib
- Indication: treatment-naive advanced ALK-positive non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02838420
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
- Interventions: Alectinib; Crizotinib
- Enrollment: 187
- Primary outcome: Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1

## Indexed commentary on ALESIA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=alesia-nct02838420

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02838420", "email": "<work email>"}; the inbox owner confirms by the emailed link.